Total population (n=1879) | |
Age†, mean (SD) | 44.0 (11.0) |
Female†, n (%) | 1782 (94.8) |
Index year†, n (%) | |
2011 | 456 (24.3) |
2012 | 512 (27.2) |
2013 | 332 (17.7) |
2014 | 367 (19.5) |
2015 | 212 (11.3) |
Geographic region†, n (%) | |
Northeast | 356 (18.9) |
North Central | 291 (15.5) |
South | 856 (45.6) |
West | 363 (19.3) |
Unknown | 13 (0.7) |
Population density†, n (%) | |
Urban | 1656 (88.1) |
Rural | 210 (11.2) |
Unknown | 13 (0.7) |
Charlson Comorbidity Index, mean (SD) | 1.3 (0.9) |
Ward SLE Risk Adjustment Index, mean (SD) | 0.8 (1.7) |
Comorbidities‡, n (%) | |
Arthralgia | 528 (28.6) |
Hypertension | 438 (23.3) |
Myositis/myalgia | 390 (20.8) |
Haematologic disorders | 384 (20.4) |
Pulmonary disease | 335 (17.8) |
Rheumatoid arthritis | 290 (15.4) |
Depression | 287 (15.3) |
Cardiac disease | 287 (15.3) |
Ophthalmologic disorders | 255 (13.6) |
*Patients with SLE identified via the IBM MarketScan Commercial Claims and Encounters Database (2010–2015) with ≥1 belimumab intravenous infusion during 2011–2015.
†Characteristic recorded on the index date; all other characteristics were recorded during the 6-month preindex period.
‡Comorbidities with an incidence of ≥10% are presented; information on patient comorbidities was collected based on a prespecified list of conditions commonly associated with SLE (eg, other inflammatory polyarthropathies, autoimmune thyroid disorders, pericarditis, myositis/myalgia, hypertension, renal disease, depression, cardiac disease, cerebrovascular disease, liver disease, pulmonary disease, osteoporosis/osteopenia), as well as conditions that may be considered in the differential diagnosis of SLE (eg, rash, fever, mouth ulcers, haematologic disorders, Reynaud’s phenomenon, ophthalmologic disorders, rheumatoid arthritis, arthralgia).